FAQ: Soligenix Appoints Tomas J. Philipson, PhD as Strategic Advisor
Summary
Soligenix Inc. has appointed Tomas J. Philipson, PhD as a Strategic Advisor to leverage his expertise in U.S. economic and healthcare policy as the company advances its lead product candidate HyBryte™ through confirmatory Phase 3 trials toward commercialization. This appointment is significant because Dr. Philipson's extensive experience and relationships will support Soligenix's mission to bring treatments for rare diseases with unmet medical needs to market.
What is the main announcement in this content?
Soligenix Inc. has appointed Tomas J. Philipson, PhD as a Strategic Advisor to provide expertise in U.S. economic and healthcare policy as the company advances its lead product candidate HyBryte™ through confirmatory Phase 3 trials.
Who is Tomas J. Philipson and what is his background?
Dr. Philipson is an expert in U.S. economic and healthcare policy with extensive academic, business, and government experience, having previously served as acting chairman of the White House Council of Economic Advisers and advised FDA, CMS, and major healthcare initiatives.
Why is this appointment significant for Soligenix?
Dr. Philipson’s expertise and relationships will be instrumental as Soligenix advances HyBryte™ through confirmatory Phase 3 trials toward commercialization, supporting the company’s mission to bring treatments for rare diseases with unmet medical needs to market.
What is Soligenix’s lead product candidate mentioned in the announcement?
HyBryte™ (SGX301 or synthetic hypericin sodium) is Soligenix’s lead product candidate, a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
What are Soligenix’s main business segments and focus areas?
Soligenix has two main business segments: Specialized BioTherapeutics (developing treatments for rare diseases including CTCL, psoriasis, and inflammatory diseases) and Public Health Solutions (developing vaccines for ricin toxin, filoviruses, and COVID-19 using ThermoVax® technology).
Where can investors find the latest news and updates about Soligenix?
The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX.
What government agencies have supported Soligenix’s Public Health Solutions business segment?
This business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).
What is Dr. Philipson’s current role outside of this advisory position?
Dr. Philipson currently serves as Managing Partner of MEDA Ventures and on several corporate boards in addition to his new role as Strategic Advisor to Soligenix.
Where can I view the full press release about this appointment?
The full press release can be viewed at https://ibn.fm/M7YEd.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 218502